Product Description
Mechanisms of Action: N/A
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: TASK Applied Science
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description

Countries in Clinic: South Africa
Active Clinical Trial Count: 1
Highest Development Phases
Phase 2: Tuberculosis, Pulmonary
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
TASK-009-SANF | P2 |
Completed |
Tuberculosis, Pulmonary |
2024-08-19 |